Fig. 8

Lower NF-YAs/NF-YAl ratio distinguishes PCa CTCs from Met. CRPC and high NF-YAs predicts the clinical outcome of PCa patients. A Left panel: Ratio of NF-YAs/NF-YAl transcripts in Met. CRPC samples compared to TCGA primary adenocarcinomas. Box plots were obtained following log2 transformation of TPM and z-score normalization of processed datasets. Right panel: Ratio of NF-YA isoforms in Met. CRPC samples compared to PCa CTCs. Raw counts of both datasets were normalized with DESeq2 algorithm and the Variance Stabilizing Transformed (vst) is represented. B Log transformed TPM and z-score normalization of NF-YAs/NF-YAl ratio in PRAD samples, stratified according to PAM50 subtypes. Wilcoxon test: ****p < 0.0001, ns, not significant. C, D Kaplan-Meier analysis of progression-free interval (PFI) in TCGA PRAD patients stratified according to high and medium/low expression of NF-YAs and NF-YAl, respectively. P values for the log rank tests are indicated. E Univariable and multivariable hazard ratio (HR) analyses of different prognostic parameters and NF-YAs expression in PRAD patients. Left table includes all patients; right table includes a subset of patients who have received either radiotherapy or chemotherapy